NOD/ShiJic-scidJcl Academic Reference List
Research Use Snapshot
NOD/ShiJic-scidJcl is an immunodeficient mouse model on a NOD genetic background, characterized by severe defects in adaptive immunity with reduced innate immune function.
This strain is widely used for human cell and tumor engraftment, supporting studies in xenograft, cancer stem cell biology, metastasis, and translational oncology.
On this page, you can browse key publications by research purpose or explore the complete reference list organized by year.
🧫 Human Xenograft & PDX Modeling
Human tumor and cell engraftment applications. Representative references are listed here when clearly indicated by the publication information on this page. For the complete list, please refer to the year-based archive below.
🧬 Cancer Stem Cell & Metastasis Biology
Recurrence and metastatic potential. This category highlights cancer stem-like properties and metastasis-related research supported by immunodeficient conditions.
🧠 Immune–Vascular Interface & Lymphatic Biology
Vascular and lymphatic structure/function insights. Publications in this section highlight analyses of lymphatic–venous communications and related in vivo dynamics.
🔬 Metabolic & Translational Oncology
Biomarkers and translational evaluation. This section highlights research focused on clinically relevant biomarkers and translational oncology applications.
🧩 Immunodeficiency Platform & Model Lineage
Model positioning and experimental context. This section is intended for publications that describe immunodeficiency characteristics, platform comparisons, or model background information when available on this page.
📚 Key Publications (Timeline)
Representative publications that define the research value of NOD/ShiJic-scidJcl. Use this timeline to understand key applications at a glance, then jump to the year-based archive for full citation details.
- Study of fluid dynamics reveals direct communications between lymphatic vessels and venous blood vessels at lymph nodes of mice (2017) — see 2017
- Clinical usefulness of 2-hydroxyglutarate as a biomarker in IDH-mutant chondrosarcoma. (2022) — see 2022
- CD44-positive Cancer Stem-like Cells as a Potential Source of Peritoneal Metastasis After Surgery. (2023) — see 2023
Related CLEA Japan product: NOD/ShiJic-scidJcl
Related CLEA Japan product: NOD/ShiJic-scidJcl
For the animal, please click here↓
: https://www.clea-japan.com/en/products/immunodeficiency/item_a0040
Inquiry:
If you have any question, please feel free to contact us from here .
2017
- Takeda K, Mori S, Kodama T.
Study of fluid dynamics reveals direct communications between lymphatic vessels and venous blood vessels at lymph nodes of mice
J Immunol Methods. 2017 Jun;445:1-9. doi: 10.1016/j.jim.2017.02.008. Epub 2017 Feb 22.PMID: 28237707
2018
- Umehara H, Maekawa Y, Koizumi F, Shimizu M, Ota T, Fouad TM, Willey J, Kaito H, Shiraishi N, Nakashima D, Akinaga S, Ueno NT.
Preclinical and phase I clinical studies of KW-2450, a dual IGF-1R/IR tyrosine kinase inhibitor, in combination with lapatinib and letrozole
Ther Adv Med Oncol. 2018 Jul 30;10:1758835918786858. doi: 10.1177/1758835918786858. PMCID: PMC6066809
- Okubo T, Nagoshi N, Kohyama J, Tsuji O, Shinozaki M, Shibata S, Kase Y, Matsumoto M, Nakamura M, Okano H.
Treatment with a Gamma-Secretase Inhibitor Promotes Functional Recovery in Human iPSC- Derived Transplants for Chronic Spinal Cord Injury
Stem Cell Reports. 2018 Nov 29;11(6):1416-1432. doi: 10.1016/j.stemcr.2018.10.022. PMCID: PMC6294244
- Yoshida T, Ri M, Kanamori T, Aoki S, Ashour R, Kinoshita S, Narita T, Totani H, Masaki A, Ito A, Kusumoto S, Ishida T, Komatsu H, Kitahata S, Chiba T, Ichikawa S, Iida S.
Potent anti-tumor activity of a syringolin analog in multiple myeloma: a dual inhibitor of proteasome activity targeting β2 and β5 subunits
Oncotarget. 2018 Jan 11;9(11):9975-9991. doi: 10.18632/oncotarget.24160. PMCID: PMC5839415
2019
- Asakawa M, Itoh M, Suganami T, Sakai T, Kanai S, Shirakawa I, Yuan X, Hatayama T, Shimada S, Akiyama Y, Fujiu K, Inagaki Y, Manabe I, Yamaoka S, Yamada T, Tanaka S, Ogawa Y.
Upregulation of cancer-associated gene expression in activated fibroblasts in a mouse model of non-alcoholic steatohepatitis
Sci Rep. 2019 Dec 20;9(1):19601. doi: 10.1038/s41598-019-56039-0. PMCID: PMC6925281
- Ito E, Miyagawa S, Takeda M, Kawamura A, Harada A, Iseoka H, Yajima S, Sougawa N, Mochizuki-Oda N, Yasuda S, Sato Y, Sawa Y.
Tumorigenicity assay essential for facilitating safety studies of hiPSC-derived cardiomyocytes for clinical application
Sci Rep. 2019 Feb 13;9(1):1881. doi: 10.1038/s41598-018-38325-5. PMCID: PMC6374479
2020
- Haramoto Y, Onuma Y, Mawaribuchi S, Nakajima Y, Aiki Y, Higuchi K, Shimizu M, Tateno H, Hirabayashi J, Ito Y.
A technique for removing tumourigenic pluripotent stem cells using rBC2LCN lectin
Regen Ther. 2020 May 19;14:306-314. doi: 10.1016/j.reth.2020.03.017. PMCID: PMC7240284
2022
- Nakagawa M, Yamaguchi M, Endo M, Machida Y, Hattori A, Tanzawa F, Tsutsumi S, Kitabayashi I, Kawai A, Nakatani F.
Clinical usefulness of 2-hydroxyglutarate as a biomarker in IDH-mutant chondrosarcoma.
J Bone Oncol. 2022 Apr 16;34:100430. doi: 10.1016/j.jbo.2022.100430. eCollection 2022 Jun.PMID: 35493690
- Komatsu SI, Kayukawa Y, Miyazaki Y, Kaneko A, Ikegami H, Ishiguro T, Nakamura M, Frings W, Ono N, Sakata K, Fujii T, Kishishita S, Kitazawa T, Endo M, Sano Y.
Determination of starting dose of the T cell-redirecting bispecific antibody ERY974 targeting glypican-3 in first-in-human clinical trial
Sci Rep. 2022 Jul 19;12(1):12312. doi: 10.1038/s41598-022-16564-x. PMCID: PMC9296674
2023
- Sihombing AM, Murata S, Shimoji M, Miyake T, Takebayashi K, Kodama H, Tokuda A, Kojima M, Ueki T, Kitamura N, Kitamura M, Mekata E, Tani M.
CD44-positive Cancer Stem-like Cells as a Potential Source of Peritoneal Metastasis After Surgery.
Anticancer Res. 2023 Jun;43(6):2491-2500. doi: 10.21873/anticanres.16416.PMID: 37247920
- Hsu CY, Yanagi T, Maeda T, Nishihara H, Miyamoto K, Kitamura S, Tokuchi K, Ujiie H.
Eribulin inhibits growth of cutaneous squamous cell carcinoma cell lines and a novel patient-derived xenograft
Sci Rep. 2023 May 27;13(1):8650. doi: 10.1038/s41598-023-35811-3. PMCID: PMC10224945
- Osaki T, Sunden Y, Warita K, Okamoto Y.
Comparison of Characterization in Two-Dimensional and Three-Dimensional Canine Mammary Gland Tumor Cell Models
Yonago Acta Med. 2023 Feb 20;66(1):7-18. doi: 10.33160/yam.2023.02.002. PMCID: PMC9937961
2024
- Nakamura K, Takahashi K, Sakaguchi I, Satoh T, Zhang L, Yanai H, Tsukumo Y.
A Novel Glycoengineered Humanized Antibody Targeting DLK1 Exhibits Potent Anti-Tumor Activity in DLK1-Expressing Liver Cancer Cell Xenograft Models †
Int J Mol Sci. 2024 Dec 19;25(24):13627. doi: 10.3390/ijms252413627. PMCID: PMC11679542
- Hsu CY, Yanagi T, Maeda T, Nishihara H, Funakoshi T, Miyamoto K, Iwamoto R, Takahashi K, Ujiie H.
Establishment of a trastuzumab-resistant extramammary Paget disease model: loss of PTEN as a potential mechanism
Br J Cancer. 2024 Jul 10;131(5):944-953. doi: 10.1038/s41416-024-02788-3. PMCID: PMC11369254
2026
- Osaki T, Kadohata T, Yasunaga M, Hishikawa S, Sunden Y, Takahashi K.
Establishment and Characterization of Canine Malignant Mesothelioma Cells
Yonago Acta Med. 2026 May 4;69(2):195-203. doi: 10.33160/yam.2026.05.007. PMCID: PMC13198971
FAQ
- Q: What is included on this page?
- A: This page provides an academic reference list for NOD/ShiJic-scidJcl, along with a related product link and an inquiry link.
Q: How are the references organized?- A: References are presented in the original "References by Year" list. You can jump to each year using the year index on this page.
Q: Which years are included in the reference list on this page?- A: The reference list on this page includes publications from 2017, 2022, and 2023.
Q: Can I browse the same references by research purpose?- A: Yes. The topic-based sections above provide a research-purpose view that points to the same publications listed in the year-based archive.
Q: Where can I find the product page for NOD/ShiJic-scidJcl?- A: The product link is provided in the "Related CLEA Japan product: NOD/ShiJic-scidJcl" section on this page.
Q: How can I contact CLEA Japan about this model?- A: The "Inquiry" section on this page includes a link to the contact form for questions about NOD/ShiJic-scidJcl.
